IL1B and infection: Baricitinib, a selective inhibitor of JAK 1 and JAK 2, inhibits the intracellular signaling pathways of cytokines, such as IL-1β, IL-6, and TNF-α (33), and as proven in our study, baricitinib inhibits mucin signaling, given that expression of these glycoproteins is regulated by these cytokines during infection and inflammation (8).